Zimmer Biomet (NYSE:ZBH) Issues FY 2026 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 8.300-8.450 for the period, compared to the consensus EPS estimate of 8.440. The company issued revenue guidance of $8.4 billion-$8.6 billion, compared to the consensus revenue estimate of $8.6 billion.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ZBH. Sanford C. Bernstein upped their price target on Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, January 21st. BTIG Research reaffirmed a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a research report on Tuesday. Canaccord Genuity Group reduced their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research report on Monday, November 10th. Finally, Wells Fargo & Company raised their price objective on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $106.10.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH traded up $1.68 on Wednesday, reaching $93.08. The company’s stock had a trading volume of 482,251 shares, compared to its average volume of 2,295,358. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $114.44. The stock has a market capitalization of $18.45 billion, a P/E ratio of 23.04, a PEG ratio of 2.29 and a beta of 0.62. The stock’s 50-day moving average is $89.97 and its two-hundred day moving average is $95.64. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, sell-side analysts forecast that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is 23.76%.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat — EPS $2.42 vs $2.38 est and revenue $2.24B, up 10.9% YoY, driven by strong hip/knee demand; this is the primary bullish catalyst. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Positive Sentiment: Analyst support — BTIG reaffirmed a Buy with a $112 price target (roughly 22% upside vs. current price), which can lend further confidence to buyers. Benzinga BTIG coverage
• Neutral Sentiment: FY‑2026 guidance set to $8.30–$8.45 EPS and revenue $8.4–$8.6B — roughly in line with consensus on EPS but slightly conservative on revenue, so guidance is more measured than bullish. Zimmer Biomet tops Q4 expectations but strikes measured tone on 2026 guidance
• Negative Sentiment: Margin contraction noted in the quarter — operating/margin pressure (partly from costs and tariffs) reduces near-term earnings leverage and explains management’s conservative tone. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
• Negative Sentiment: Analyst caution — Needham reaffirmed a Hold, and management flagged tariff and margin headwinds that could limit upside until FCF/margin trends improve. Benzinga Needham coverage

Institutional Investors Weigh In On Zimmer Biomet

Hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $37,000. Mpwm Advisory Solutions LLC acquired a new position in Zimmer Biomet during the third quarter worth $65,000. Palisade Asset Management LLC purchased a new position in Zimmer Biomet in the third quarter worth $70,000. Caitong International Asset Management Co. Ltd lifted its holdings in Zimmer Biomet by 449.7% in the third quarter. Caitong International Asset Management Co. Ltd now owns 786 shares of the medical equipment provider’s stock valued at $77,000 after acquiring an additional 643 shares during the period. Finally, Parallel Advisors LLC boosted its position in shares of Zimmer Biomet by 43.4% during the 3rd quarter. Parallel Advisors LLC now owns 895 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 271 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.